GO:1901184 regulation of ERBB signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1901184 (regulation of ERBB signaling pathway) is a biological process that modulates the frequency, rate, or extent of signaling through the ERBB family of receptor tyrosine kinases (EGFR/ERBB1, ERBB2, ERBB3, ERBB4).
• ERBB signaling is controlled at multiple levels, including ligand availability, receptor dimerization, redox-dependent modifications, and negative feedback loops.
• Dysregulation of ERBB signaling is implicated in many cancers, including colorectal, cervical, and other solid tumors, making it a major therapeutic target.
• Noncoding RNAs, such as microRNAs and long noncoding RNAs, are emerging as key regulators of ERBB pathway activity in cancer.
• The neuregulin-1/ErbB axis also regulates cardiovascular and vascular signaling, highlighting the pathway's broad physiological roles.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of regulatory nodes within the ERBB signaling network.
Description
The ERBB signaling pathway is a fundamental cell-signaling cascade that controls proliferation, survival, differentiation, and migration in metazoans. It is initiated by extracellular ligands such as epidermal growth factor (EGF) and neuregulins, which bind to ERBB family receptor tyrosine kinases (EGFR/ERBB1, ERBB2, ERBB3, ERBB4), leading to receptor dimerization, autophosphorylation, and activation of downstream effectors. Because the intensity and duration of ERBB signals must be tightly controlled, cells have evolved numerous regulatory mechanisms that collectively constitute the Gene Ontology term GO:1901184, regulation of ERBB signaling pathway. Understanding this regulation is critical for both basic biology and clinical translation, as aberrant ERBB signaling drives multiple cancers and cardiovascular disorders. Research into GO:1901184 spans ligand-receptor interactions, redox modulation, microRNA-mediated silencing, and long noncoding RNA (lncRNA) interference, with model systems ranging from Drosophila to human cell lines. This article synthesizes current knowledge on the regulatory mechanisms, key genes, disease relevance, and experimental strategies for studying regulation of ERBB signaling pathway.
regulation of ERBB signaling pathway At A Glance
| GO ID | GO:1901184 |
|---|---|
| GO term | regulation of ERBB signaling pathway |
| Ontology | biological_process |
| Synonym | regulation of EGF receptor family signaling pathway; regulation of EGFR family signaling pathway; regulation of ErbB signaling; regulation of ERBB signalling pathway |
| Major function | Modulates the frequency, rate, or extent of signaling through ERBB family receptor tyrosine kinases |
| Related pathways | EGFR signaling, neuregulin/ErbB signaling, MAPK/ERK, PI3K/AKT |
| Key regulators | Ligands (EGF, neuregulins), microRNAs, lncRNAs, redox modifiers, phosphatases |
| Disease relevance | Cancer (colorectal, cervical, breast, lung), cardiovascular disorders |
| Research models | Cell lines, Drosophila, mouse models, CRISPR-engineered cells |
What Is GO:1901184?
According to the Gene Ontology, GO:1901184 (regulation of ERBB signaling pathway) is defined as any process that modulates the frequency, rate, or extent of ERBB signaling pathway. In other words, it encompasses all molecular events that tune the strength, duration, or spatial pattern of signals transduced by ERBB family receptors, without being part of the core signaling cascade itself. This regulation can occur at the level of ligand production, receptor expression, post-translational modifications, or downstream feedback loops.
Why Is regulation of ERBB signaling pathway Important in Cell Biology?
Regulation of ERBB signaling is essential for normal development and tissue homeostasis, and its disruption is a hallmark of many diseases, especially cancer. Because ERBB receptors are among the most frequently altered oncogenes, understanding how their signaling is regulated provides direct opportunities for therapeutic intervention. Moreover, the pathway's role in cardiovascular biology, as shown by neuregulin-1/ErbB signaling in vascular and angiogenic processes, underscores its broad physiological significance. Studying GO:1901184 helps researchers identify regulatory nodes that can be targeted to fine-tune ERBB activity, potentially overcoming resistance to current EGFR inhibitors.
• ERBB signaling controls fundamental cellular processes such as proliferation, survival, and differentiation.
• Dysregulation of ERBB signaling is a driving force in many cancers, including colorectal and cervical cancer.
• Redox-dependent regulation of EGFR adds a layer of control that can be exploited for therapy.
• MicroRNAs and lncRNAs are key regulators of ERBB signaling in cancer, offering new biomarkers and targets.
• Neuregulin-1/ErbB signaling is critical for cardiovascular development and angiogenesis.
• Drosophila models have provided conserved insights into EGFR signaling regulation.
• Understanding regulation of ERBB signaling can inform strategies to overcome drug resistance.
• CRISPR-based editing enables precise manipulation of regulatory genes for functional studies.
• The pathway is a major focus of pharmaceutical development, with numerous inhibitors in clinical use.
• Regulation of ERBB signaling intersects with other signaling networks, making it a systems-level research priority.
What Happens During regulation of ERBB signaling pathway?
Ligand availability and receptor activation
In simple terms: The first step in controlling ERBB signaling is controlling when and where the activating ligands are present.
ERBB signaling is initiated when ligands such as EGF or neuregulins bind to ERBB receptors, causing dimerization and activation. Regulation at this stage includes modulation of ligand production, sequestration, or cleavage, which directly affects the frequency and extent of receptor activation. For example, neuregulin-1 is a key ligand for ERBB3 and ERBB4 in cardiovascular tissues, and its availability is tightly regulated.
Redox-dependent modulation of receptor activity
In simple terms: Chemical modifications caused by reactive oxygen species can switch ERBB signaling on or off.
Redox-dependent regulation of EGFR involves reversible oxidation of critical cysteine residues, which can alter receptor kinase activity and downstream signaling. This layer of control allows cells to integrate oxidative stress signals with growth factor signaling. Natural compounds such as hexameric procyanidins can inhibit colorectal cancer cell growth through both redox and non-redox regulation of the epidermal growth factor signaling pathway.
Negative feedback and phosphatases
In simple terms: Cells use brakes, such as phosphatases, to turn off ERBB signals after they have done their job.
ERBB signaling is attenuated by negative feedback loops involving phosphatases and ubiquitin ligases that dephosphorylate or degrade activated receptors. These mechanisms ensure that signaling is transient and spatially confined. Dysregulation of these feedback loops can lead to sustained ERBB activity, a common feature in cancer.
Noncoding RNA-mediated regulation
In simple terms: Small RNA molecules and long noncoding RNAs can dial down or up the ERBB pathway.
MicroRNAs can directly target mRNAs encoding ERBB receptors or downstream effectors, thereby modulating pathway output. In cervical cancer, specific microRNAs have been shown to regulate the EGFR signaling pathway, affecting tumor cell behavior. Additionally, long noncoding RNA HOXC-AS3 enhances cervical cancer progression by activating the ErbB signaling pathway, illustrating positive regulation by a lncRNA.
Cross-talk with other signaling pathways
In simple terms: ERBB signaling does not work in isolation; other pathways can influence its strength.
ERBB signaling intersects with G-protein coupled receptor pathways, integrin signaling, and cytokine signaling, which can modulate its activity. For instance, neuregulin-1/ErbB signaling in the cardiovascular system cross-talks with vascular endothelial growth factor (VEGF) pathways to regulate angiogenesis. Such cross-talk is a form of regulation that adjusts ERBB output according to the cellular context.
Key Genes Involved in GO:1901184 regulation of ERBB signaling pathway
The following genes and proteins are central to the regulation of ERBB signaling pathway, as supported by the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| EGFR (ERBB1) | Receptor tyrosine kinase that initiates signaling upon ligand binding | Major drug target; mutations and overexpression in many cancers |
| ERBB2 (HER2) | Co-receptor that enhances signaling; no known ligand | Amplified in breast and other cancers; target of trastuzumab |
| ERBB3 | Kinase-dead receptor that partners with other ERBBs | Key activator of PI3K/AKT; implicated in cancer and cardiovascular biology |
| ERBB4 | Receptor for neuregulins; involved in development | Roles in cardiovascular and neuronal signaling |
| NRG1 (Neuregulin-1) | Ligand for ERBB3/ERBB4 | Regulates vascular signaling and angiogenesis |
| EGF | Ligand for EGFR | Prototype ligand; used to activate signaling experimentally |
| MIR21 | MicroRNA that can modulate EGFR signaling | Potential biomarker and therapeutic target in cervical cancer |
| MIR7 | MicroRNA targeting EGFR pathway components | Regulates EGFR signaling in cancer |
| HOXC-AS3 | Long noncoding RNA that activates ErbB signaling | Promotes cervical cancer progression |
| PTPN1 (PTP1B) | Protein tyrosine phosphatase that dephosphorylates EGFR | Negative regulator of ERBB signaling |
| CBL | E3 ubiquitin ligase that targets activated EGFR for degradation | Controls receptor downregulation |
| SRC | Non-receptor tyrosine kinase that can phosphorylate EGFR | Modulates ERBB signaling and cancer progression |
| MAPK1 (ERK2) | Downstream kinase in ERBB signaling | Effector of proliferation signals |
| AKT1 | Downstream kinase in PI3K/AKT pathway | Mediates survival signals from ERBB |
| STAT3 | Transcription factor activated by ERBB signaling | Regulates gene expression and tumorigenesis |
| PTEN | Phosphatase that antagonizes PI3K/AKT | Negative regulator of ERBB downstream signaling |
| GAB1 | Docking protein that amplifies ERBB signaling | Scaffold for PI3K and other effectors |
How Is regulation of ERBB signaling pathway Regulated?
Regulation of ERBB signaling is achieved through a combination of ligand availability, receptor post-translational modifications (including redox-dependent changes), negative feedback by phosphatases and ubiquitin ligases, and noncoding RNA-mediated control. For example, microRNAs can directly repress EGFR expression or that of its downstream effectors, thereby dampening pathway activity. Conversely, lncRNAs such as HOXC-AS3 can enhance ErbB signaling, promoting cancer progression. Redox regulation adds another layer, where reactive oxygen species modify EGFR cysteine residues to modulate kinase activity. These diverse mechanisms ensure that ERBB signaling is appropriately tuned in space and time, and their disruption contributes to disease.
regulation of ERBB signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| EGFR | Colorectal cancer, lung cancer | CRISPR knockout in HCT116 or A549 cells |
| ERBB2 | Breast cancer | Point mutation knock-in in SK-BR-3 cells |
| MIR21 | Cervical cancer | Overexpression or knockout in HeLa cells |
| HOXC-AS3 | Cervical cancer | Knockdown or overexpression in SiHa cells |
| NRG1 | Cardiovascular disorders | Knockout in mouse models or iPSC-derived cardiomyocytes |
Cancer
Dysregulation of ERBB signaling is a hallmark of many cancers. In colorectal cancer, EGFR-targeted therapies are used clinically, but resistance often emerges due to compensatory regulatory mechanisms. In cervical cancer, microRNAs and lncRNAs that regulate the EGFR/ErbB pathway influence tumor growth and progression. Hexameric procyanidins inhibit colorectal cancer cell growth by modulating redox and non-redox regulation of EGFR signaling, highlighting the therapeutic potential of targeting regulatory nodes.
Cardiovascular disease
Neuregulin-1/ErbB signaling plays critical roles in vascular signaling and angiogenesis, and its dysregulation has been implicated in cardiovascular disorders. Understanding how this pathway is regulated could lead to new therapies for heart failure and vascular diseases.
Other diseases
Altered ERBB signaling regulation has been linked to developmental disorders and neurodegenerative conditions, although the exact mechanisms are still being elucidated. The broad expression of ERBB receptors across tissues suggests that regulatory defects could contribute to diverse pathologies.
From regulation of ERBB signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate regulator alter ERBB signaling? | CRISPR knockout cell line (e.g., EGFR, ERBB2, or regulator gene) |
| Does a specific point mutation in EGFR affect its regulation? | CRISPR point mutation knock-in (e.g., L858R or T790M) |
| How does a tagged version of ERBB2 behave in live cells? | Knock-in of fluorescent or epitope tag at endogenous locus |
| What is the effect of overexpressing a microRNA on ERBB signaling? | Stable overexpression of miRNA in cancer cell lines |
| Can a lncRNA activate ErbB signaling? | Overexpression or knockout of lncRNA in cervical cancer cells |
| Is a redox-sensitive cysteine required for EGFR regulation? | Point mutation of cysteine to serine via CRISPR |
How to Study the regulation of ERBB signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcriptome changes | Identify genes differentially expressed upon regulator knockout |
| Phosphoproteomics | Phosphorylation status of signaling proteins | Map ERBB downstream signaling |
| Western blot | Protein expression and phosphorylation | Validate receptor activation and downstream effectors |
| Immunofluorescence | Subcellular localization of ERBB receptors | Study receptor trafficking and dimerization |
| CRISPR screening | Phenotypic effects of gene knockouts | Discover novel regulators of ERBB signaling |
| MicroRNA profiling | Expression levels of microRNAs | Identify miRNAs regulating EGFR pathway |
| LncRNA knockdown | Effect of lncRNA loss on signaling | Study HOXC-AS3 in cervical cancer |
| Cell viability assay | Proliferation and survival | Assess impact of regulatory perturbations |
Genomic and transcriptomic profiling
RNA-seq and microarray analyses can identify changes in gene expression upon perturbation of regulatory genes in the ERBB pathway. For example, knockdown of HOXC-AS3 alters the expression of ErbB signaling components in cervical cancer cells.
Proteomic and phosphoproteomic analysis
Mass spectrometry-based phosphoproteomics allows comprehensive mapping of phosphorylation events downstream of ERBB receptors, revealing regulatory feedback loops. This approach can quantify changes in receptor autophosphorylation and downstream kinase activity upon genetic manipulation.
Imaging and live-cell assays
Fluorescence microscopy of tagged ERBB receptors can visualize receptor trafficking, dimerization, and internalization in real time. These methods are useful for studying how regulatory proteins affect receptor localization and dynamics.
Functional assays
Cell proliferation, migration, and apoptosis assays are used to assess the functional consequences of altered ERBB signaling regulation. For instance, treatment with hexameric procyanidins inhibits colorectal cancer cell growth, which can be measured by MTT or colony formation assays.
How CRISPR Can Be Used to Study GO:1901184 regulation of ERBB signaling pathway
Knockout
CRISPR knockout of ERBB receptors or their regulators (e.g., EGFR, ERBB2, or phosphatases) can abolish specific signaling nodes, allowing researchers to determine their contribution to pathway output. For example, knocking out EGFR in colorectal cancer cell lines reduces downstream MAPK and AKT activation.
Point Mutation
Introducing point mutations such as EGFR L858R or T790M via CRISPR enables study of how specific amino acid changes affect receptor regulation, drug sensitivity, and downstream signaling. These models are valuable for understanding resistance mechanisms to EGFR inhibitors.
Knock-in
Knock-in of tags (e.g., GFP, HA) at endogenous ERBB loci allows real-time imaging and biochemical analysis of receptor dynamics under native regulatory control. This approach preserves physiological expression levels and avoids artifacts from overexpression.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can elevate levels of regulatory proteins or noncoding RNAs to study their gain-of-function effects on ERBB signaling. For instance, overexpression of HOXC-AS3 enhances ErbB signaling and promotes cervical cancer progression.
How EDITGENE Supports regulation of ERBB signaling pathway Research
Researchers studying regulation of ERBB signaling pathway-related genes often need to determine whether a candidate gene is causally involved in modulating receptor activity, downstream signaling, or disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such functional studies with high precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for regulation of ERBB signaling pathway research.
Frequently Asked Questions About regulation of ERBB signaling pathway
What is GO:1901184?
GO:1901184 is the Gene Ontology term for regulation of ERBB signaling pathway, defined as any process that modulates the frequency, rate, or extent of signaling through ERBB family receptors.
What genes are involved in regulation of ERBB signaling pathway?
Key genes include EGFR, ERBB2, ERBB3, ERBB4, NRG1, EGF, MIR21, MIR7, HOXC-AS3, PTPN1, CBL, and SRC, among others.
How is ERBB signaling regulated?
ERBB signaling is regulated by ligand availability, receptor post-translational modifications (including redox changes), negative feedback by phosphatases and ubiquitin ligases, and noncoding RNAs.
What diseases are associated with dysregulation of ERBB signaling?
Dysregulation of ERBB signaling is associated with various cancers (colorectal, cervical, breast, lung) and cardiovascular disorders.
What is the role of microRNAs in ERBB signaling?
MicroRNAs can directly target mRNAs encoding ERBB receptors or downstream effectors, thereby modulating pathway activity in cancer.
How can CRISPR be used to study regulation of ERBB signaling?
CRISPR can create knockouts, point mutations, knock-ins, or overexpression models to dissect the function of specific regulatory genes in the ERBB pathway.
What is the role of redox regulation in EGFR signaling?
Redox-dependent regulation involves reversible oxidation of cysteine residues in EGFR, which can modulate its kinase activity and downstream signaling.
What is the significance of neuregulin-1/ErbB signaling in the cardiovascular system?
Neuregulin-1/ErbB signaling regulates vascular signaling and angiogenesis, and its dysregulation is implicated in cardiovascular disorders.
How do long noncoding RNAs regulate ErbB signaling?
Long noncoding RNAs such as HOXC-AS3 can activate ErbB signaling, promoting cancer progression.
What model systems are used to study regulation of ERBB signaling?
Common models include human cancer cell lines, Drosophila, mouse models, and CRISPR-engineered cells.
Conclusion
Regulation of ERBB signaling pathway (GO:1901184) is a critical biological process that ensures proper control of cell growth, survival, and differentiation. Its dysregulation underlies numerous diseases, particularly cancer and cardiovascular disorders, making it a prime target for therapeutic intervention. Advances in CRISPR-based models and high-throughput technologies are accelerating the discovery of novel regulatory mechanisms and their roles in disease. Continued research into this pathway will likely yield new strategies for precision medicine.
References
- 1. Sabbah DA et al.. 2020. Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors.. Curr Top Med Chem 20(10):815-834 PMID: 32124699
- 2. Heppner DE et al.. 2016. Redox-dependent regulation of epidermal growth factor receptor signaling.. Redox Biol 8:24-7 PMID: 26722841
- 3. Unknown. 2004. EGFR-targeted therapy for patients with colorectal cancer: patient management and future directions.. ONS News 19(9 Suppl):53-4 PMID: 15478587
- 4. Daveri E et al.. 2021. Hexameric procyanidins inhibit colorectal cancer cell growth through both redox and non-redox regulation of the epidermal growth factor signaling pathway.. Redox Biol 38:101830 PMID: 33338921
- 5. Hemmat N et al.. 2020. Role of microRNAs in epidermal growth factor receptor signaling pathway in cervical cancer.. Mol Biol Rep 47(6):4553-4568 PMID: 32383136
- 6. Hedhli N et al.. 2014. Cardiovascular effects of neuregulin-1/ErbB signaling: role in vascular signaling and angiogenesis.. Curr Pharm Des 20(30):4899-905 PMID: 24283954
- 7. Harden N. 2017. New Insights from Drosophila into the Regulation of EGFR Signaling.. Methods Mol Biol 1652:37-42 PMID: 28791632
- 8. Zhao R et al.. 2021. Long noncoding RNA HOXC-AS3 enhances the progression of cervical cancer via activating ErbB signaling pathway.. J Mol Histol 52(5):991-1006 PMID: 34387789
